bioRxiv Science⌕ Search

Biology subjects

Sivakumar, A.

Publications and source records attributed to Sivakumar, A..

12 recordsLinked to original sources

Muon Reduces the Training Cost of Regulatory DNA Transformers

Gene-therapy design depends on identifying regulatory sequences that drive the right level, timing, and cell-type specificity of expression. Regulatory DNA models offer a way to prioritize such sequences computationally before committing candidates to biological testing. Biological validation involves DNA synthesis, cloning, cell culture, sequencing, and functional screening, so training compute is part of the same constrained discovery pipeline rather than an isolated modeling expense. Reducing the compute required to reach a target pretraining quality could shift time and budget toward larger candidate screens, additional assays, more cell contexts, and broader follow-up validation. Given that Adam-style optimizers are widely used for training genomic sequence models, we study whether Muon can provide a more compute-efficient alternative for regulatory DNA pretraining. We provide an in-depth analysis by training Transformer models (26M-420M parameters) on ENCODE cis-regulatory sequences with Adam and Muon while holding architecture, data, and non-optimizer hyperparameters fixed and varying optimizer family, norm-control scheme, learning rate, and model width. In the largest-scale matched-target comparison, Muon reaches Adam-matched perplexity targets with a median FLOP reduction of 35.4% and a median wall-clock time reduction of 38.5%. The analysis further shows that optimizer rankings depend on norm control: independent weight decay pairs more favorably with Muon than Hyperball in this setting. These findings indicate that optimizer update structure and norm-control choices are practical levers for reducing the training resources required to reach matched perplexity targets in regulatory DNA pretraining.

genomics↗

Computational design of a multi-epitope vaccine against M. tuberculosis

BackgroundTuberculosis remains a leading global infectious killer, with BCG offering inconsistent adult protection and rising drug-resistant strains demanding novel vaccine strategies. We report the first multi-epitope vaccine construct simultaneously targeting three previously unexplored Mycobacterium tuberculosis virulence proteins; EccB3, MycP, and polyketide synthase which collectively govern nutrient acquisition, ESX secretion integrity, and innate immune evasion. MethodsUsing a reverse vaccinology pipeline, B-cell, CTL, and HTL epitopes were predicted, filtered for allergenicity, toxicity, and IFN-{gamma} induction, then assembled into an 823-residue chimeric construct incorporating beta-defensin and PADRE adjuvants with AAY/GPGPG linkers, covering [~]90% global HLA diversity. The construct underwent AlphaFold structure prediction, 3DRefine refinement, disulfide engineering, PROCHECK/ProSA validation, ClusPro 2.0 docking against TLR1/TLR2, and C-IMMSIM immune simulation. ResultsThe construct (82.3 kDa, instability index 32.48) showed strong structural quality (94.7% favoured Ramachandran residues), stable TLR1/TLR2 binding (weighted energy: -1,371.0 kcal/mol), and robust in silico immune responses and durable memory cell formation following booster simulation. ConclusionThis computationally validated construct represents a promising multi-target TB vaccine candidate warranting experimental advancement.

bioinformatics↗

Programming T cells for Early Cancer Detection with Customized Protease-Activatable Receptors

Early cancer detection has the potential to reduce cancer mortality, yet endogenous tumor-shed biomarkers lack sensitivity for early-stage disease. We report OncoSCOUT, a cancer detection strategy using T cells engineered with protease-activatable receptors (PARs) that conditionally recognize tumor cells and release a synthetic biomarker for detection in urine. These PARs comprise masked synthetic Notch receptors in which antigen binding is blocked by a peptide mimotope tethered via a protease-cleavable linker. We demonstrate that requiring both extracellular protease activity and tumor antigen recognition improves spatial specificity and minimizes off-tumor activation of PAR T cells in vivo. To identify tumor-selective PARs, we adoptively transferred a HER2-targeted PAR library displaying [~]160,000 unique 4-mer amino acid linkers and discovered multiple variants significantly enriched in a HER2-positive cancer xenograft model. Using a single customized PAR, we show that OncoSCOUT can detect total tumor burdens as small as 10-30 mm3 with significantly improved sensitivity than the protein biomarker CA 15-3 or a 20-plex circulating tumor DNA (ctDNA) assay.

bioengineering↗

Cystinosin is involved in Na+/H+ Exchanger 3 trafficking in the proximal tubular cells: new insights in the renal Fanconi syndrome in cystinosis

Cystinosis is a systemic lysosomal storage disease resulting from a defective CTNS gene, leading to the accumulation of cystine in all organs. Despite the ubiquitous expression of cystinosin, the renal Fanconi syndrome (FS) is the first manifestation of cystinosis that presents early in life of the patients while other complications appear years later. Additionally, the cystine reduction therapy, cysteamine, does not prevent the FS. While the matter is still unresolved, it is apparent that specific function(s) of cystinosin in the proximal tubular cells (PTCs) beyond cystine transport explain the early tubular defects in cystinosis. Here, we report a novel interaction of cystinosin with the sodium/hydrogen (Na+/H+) exchanger proteins in the endosomes in both yeast and mammalian cells. One isoform of Na+/H+ exchanger, NHE3, is a major absorptive sodium transporter at the apical membrane of the proximal tubules. Cystinosin was found to play a significant role in NHE3 subcellular localization, trafficking, and resulting sodium uptake in PTCs. Interestingly, introduction of CTNS successfully rescued these defects in CTNS-deficient PTCs, whereas CTNS-LKG, the lysosomal and plasma membrane isoform of cystinosin, did not. NHE3 mislocalization was confirmed in Ctns-/- mice and cystinosis patient kidney. Interestingly, transplantation of wild-type hematopoietic stem and progenitor cells in Ctns-/- mice restored NHE3 expression at the brush border membrane. This study uncovers a new role of cystinosin in the trafficking of NHE3 in the PTCs that is evolutionary conserved, offering new insights in the pathogenesis of the renal FS in cystinosis and potential new therapeutic avenue for this pathology. SignificanceThis study reveals a new role of cystinosin in the trafficking of NHE3, the Na+/H+ exchanger in the proximal tubular cells (PTCs) in the kidney. NHE3 contributes to the majority of renal sodium absorption and is essential for maintaining the homeostasis of the PTCs. Thus, this study offers new molecular insights in the endosomal trafficking of NHE3 and provides a new mechanism that may explain the underlying pathogenesis and early onset of the renal Fanconi syndrome in cystinosis. Additionally, these findings provide potential new drug targets for this pathology and are also relevant to our ongoing stem cell gene therapy clinical trial for cystinosis, offering valuable information on the potential impact of hematopoietic stem cell transplantation on renal Fanconi syndrome.

molecular biology↗

Analysis of Curcumin and Piperine for Breast Cancer Prevention and Treatment via Simulation and Artificial Intelligence Methods

From published literature, the combined properties of Curcumin and Piperine infers that the two molecules are potential preventative agents. The nutraceutical combination of Curcumin and Piperine may aid in breast cancer prevention by enhancing Curcumins anti-inflammatory and antioxidant effects. In this paper, we demonstrate the following analysis on these two nutraceutical drug molecules in the effort to replicate these inferences in-silico: Drug Synergy Analysis, Molecular Docking and Simulation of Dose-Response curves. We have predicted the synergy (i.e., the effect of two drug molecules when administered simultaneously) between the two molecules on the basis of the Bliss Additivity Score. These scores have been predicted by devising a deep learning model using neural networks to determine that the two molecules of interest are synergetic in nature (i.e., one molecule improves the effectiveness of the other). The data used for this model has been extracted from the DrugComb database and filtered to having drug combinations under the MCF7 cell line. The drug molecules are converted from its original SMILES representation to the ECFP6 molecular fingerprint format prior to training the data with the output feature as the Bliss score. In this work we also study the interactions between the molecules of interest and protein targets which are of interest (TRPV1 and STAT3) via Molecular Docking. From this, we have been able to determine the binding affinity of the two ligands of interest by docking simultaneously. We have also identified the coordinates of the binding sites of the respective ligands and other potential binding sites for effective binding. From the binding free energies simulated from molecular docking, we have derived the IC50 values using the Cheng-Prusoff Equation. From these IC50 values we have derived the monotherapy dose-response curves with respect to the activation of each the protein targets and the molecules of interest over a range of molar concentrations (0.01um to 100um) using the 4 - parameter logistic curve equation. Furthermore, we have devised a 3D heatmap indicating the combined effectiveness of Curcumin and Piperine from the 4 - parameter log - logistic curve of the Loewes Additivity Model over each of the protein targets in focus.

bioinformatics↗

Antigen-specific T cell immunotherapy by in vivo mRNA delivery

Immunotherapy has shown promise for treating patients with autoimmune diseases or cancer, yet treatment is associated with adverse effects associated with global activation or suppression of T cell immunity. Here, we developed antigen-presenting nanoparticles (APNs) to selectively engineer disease antigen (Ag)-specific T cells by in vivo mRNA delivery. APNs consist of a lipid nanoparticle core functionalized with peptide-major histocompatibility complexes (pMHCs), facilitating antigen-specific T cell transfection through cognate T cell receptor-mediated endocytosis. In mouse models of type 1 diabetes and multiple myeloma, APNs selectively deplete autoreactive T cells leading to durable control of glycemia, and engineer virus-specific T cells with anti-cancer chimeric antigen receptors (CARs), achieving comparable therapeutic outcome as virally transduced ex vivo CAR. Overall, our work supports the use of APNs to engineer disease-relevant T cells in vivo as Ag-specific immunotherapy for autoimmune disorders and cancer.

bioengineering↗

Benzylic Trifluoromethyl Accelerates 1,6-Elimination Toward Rapid Probe Activation

Activity-based detection of hydrogen sulfide in live cells can expand our understanding of its reactivity and complex physiological effects. We have discovered a highly efficient method for fluorescent probe activation, which is driven by H2S-triggered 1,6-elimination of an -CF3-benzyl to release resorufin. In detecting intracellular H2S, 4-azido-(-CF3)-benzyl resorufin offers significantly faster signal generation and improved sensitivity compared to 4-azidobenzyl resorufin. Computed free energy profiles for the 1,6-elimination process support the hypothesis that a benzylic CF3 group can reduce the activation energy barrier toward probe activation. This novel probe design allows for near-real-time detection of H2S in HeLa cells under stimulation conditions.

biochemistry↗

A CXCL12 morphogen gradient uncovers lung endothelial heterogeneity and promotes distal vascular growth

In adults, there is a growing amount of data uncovering the cellular diversity of the pulmonary circulation and mechanisms governing vascular repair after injury, however, molecular and cellular mechanisms contributing to the morphogenesis and growth of the pulmonary vasculature during embryonic development are less clear. Importantly, deficits in vascular development lead to a large number of lung diseases in children, indicating a need to uncover fetal programs that promote pulmonary vascular growth. To address this, we used a transgenic mouse reporter for expression of Cxcl12, an arterial hallmark gene, and performed single-cell RNA sequencing on isolated Cxcl12-DsRed+ endothelium to assess cellular heterogeneity within pulmonary endothelium. Combining cell annotation, gene ontology analysis, and spatial transcriptomics allowed us to segregate the developing artery into spatially and functionally distinct novel subpopulations. In addition, expression of Cxcl12 suggests a morphogen gradient from arteries to capillaries, suggesting directed cell migration for pulmonary vascular development. Disruption of this gradient led to abnormal branching and pulmonary vascular hypoplasia. These data provide evidence for arterial endothelial functional heterogeneity and reveal conserved signaling mechanisms essential for pulmonary vascular development.

developmental biology↗

Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens

CAR T cell immunotherapy relies on CAR targeting of tumor-associated antigens, yet heterogenous antigen expression, interpatient variation, and off-tumor expression by healthy cells remain barriers. Here, we develop synthetic antigens to sensitize solid tumors for recognition and elimination by CAR T cells. Unlike tumor-associated antigens, we design synthetic antigens that are orthogonal to endogenous proteins to eliminate off-tumor targeting and that have a small genetic footprint to facilitate efficient tumor delivery to tumors by viral vectors. Using the RSV-F camelid single-domain antibody (VHH) as a synthetic antigen, we show that adoptive transfer of VHH CAR T cells to mice bearing VHH expressing tumors reduced tumor burden in multiple syngeneic mouse models of cancer, improved survival, induced epitope spread, and protected against tumor rechallenge. Our work supports in situ delivery of synthetic antigens to treat antigen low or negative tumors with CAR T cells.

bioengineering↗

Genomic loci mispositioning in Tmem120a knockout mice yields latent lipodystrophy

Little is known about the proteins that direct the highly conserved patterns of spatial genome organisation in fat. Here we report that adipocyte-specific knockout of the gene encoding nuclear envelope protein Tmem120a disrupts fat genome organisation, thus causing a novel lipodystrophy syndrome. Tmem120a deficiency broadly suppresses lipid metabolism pathway gene expression and induces myogenic gene expression by repositioning genes, enhancers and miRNA-encoding loci between the nuclear periphery and interior. Tmem120a-/- mice, particularly females, exhibit a lipodystrophy syndrome similar to human familial partial lipodystrophy FPLD2, with profound insulin resistance and metabolic defects that manifests upon exposure to an obesogenic diet. Interestingly, similar genome organisation defects occurred in cells from FPLD2 patients that harbour nuclear envelope protein laminA mutations. Our data suggest TMEM120A may mediate/instigate novel categories of adipose tissue dysfunction across the adiposity spectrum and provide a new miRNA-based mechanism possibly driving the unexplained muscle hypertrophy in human lipodystrophy.

cell biology↗

Activity-based urinary biomarkers of response and resistance to checkpoint blockade immunotherapy

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, yet most patients do not derive clinical benefit and responders can acquire resistance to therapy. Noninvasive biomarkers are needed to indicate early on-treatment response and resistance mechanisms. Here we developed ImmuNe Sensors for monItorinG cHeckpoint blockade Therapy (INSIGHT), which comprises a library of mass-barcoded peptide substrates conjugated to PD1 antibodies, as therapeutic sensors. Following systemic administration, INSIGHT carries out the dual role of reinvigorating T cell function and profiling T cell and tumor proteases by the release of cleaved peptides into urine for noninvasive detection by mass spectrometry. We show that an PD1 therapeutic sensor for Granzyme B discriminates early treatment responses before tumor volumes significantly diverge from isotype controls in murine models of colorectal cancer. To differentiate mechanisms of resistance by multivariate analysis, we design a mass-barcoded, 14-plex INSIGHT library to profile proteases differentially expressed by tumors harboring B2m or Jak1 loss-of-function mutations. We find that binary classifiers trained on urine samples indicate response to PD-1 therapy as early as the start of the second dose, and discriminate B2m from Jak1 resistance with high sensitivity and specificity (AUROCs > 0.9). Our data supports the use of activity-based biomarkers for early on-treatment response assessment and classification of refractory tumors based on resistance mechanisms. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=109 SRC="FIGDIR/small/420265v2_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@12ce799org.highwire.dtl.DTLVardef@118fcc5org.highwire.dtl.DTLVardef@17b227eorg.highwire.dtl.DTLVardef@115a7fc_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗

Prediction of peptide binding to MHC Class I proteins in the age of deep learning

Binding of peptides to Major Histocompatibility Complex (MHC) proteins is a critical step in immune response. Peptides bound to MHCs are recognized by CD8+ (MHC Class I) and CD4+ (MHC Class II) T-cells. Successful prediction of which peptides will bind to specific MHC alleles would benefit many cancer immunotherapy appications. Currently, supervised machine learning is the leading computational approach to predict peptide-MHC binding, and a number of methods, trained using results of binding assays, have been published. Many clinical researchers are dissatisfied with the sensitivity and specificity of currently available methods and the limited number of alleles for which they can be applied. We evaluated several recent methods to predict peptide-MHC Class I binding affinities and a new method of our own design (MHCnuggets). We used a high-quality benchmark set of 51 alleles, which has been applied previously. The neural network methods NetMHC, NetMHCpan, MHCflurry, and MHCnuggets achieved similar best-in-class prediction performance in our testing, and of these methods MHCnuggets was significantly faster. MHCnuggets is a gated recurrent neural network, and the only method to our knowledge which can handle peptides of any length, without artificial lengthening and shortening. Seventeen alleles were problematic for all tested methods. Prediction difficulties could be explained by deficiencies in the training and testing examples in the benchmark, suggesting that biological differences in allele-specific binding properties are not as important as previously claimed. Advances in accuracy and speed of computational methods to predict peptide-MHC affinity are urgently needed. These methods will be at the core of pipelines to identify patients who will benefit from immunotherapy, based on tumor-derived somatic mutations. Machine learning methods, such as MHCnuggets, which efficiently handle peptides of any length will be increasingly important for the challenges of predicting immunogenic response for MHC Class II alleles.\n\nAuthor SummaryMachine learning methods are a popular approach for predicting whether a peptide will bind to Major Histocompatibility Complex (MHC) proteins, a critical step in activation of cytotoxic T-cells. The input to these methods is a peptide sequence and an MHC allele of interest, and the output is the predicted binding affinity. MHC Class I and II proteins bind peptides of 8-11 amino acids and 16-26 amino acids respectively. This has been an obstacle for machine learning, because the methods used to date can only handle fixed-length inputs. We show that a recently developed technique known as gated recurrent neural networks can handle peptides of variable length and predict peptide-MHC binding as well or better than existing methods, at substantially faster speeds. Our results have implications for the hundreds of MHC alleles that cannot be predicted with current methods.

bioinformatics↗